Skip to main content
DOUBLE MEDICAL TECHNOLOGY INC. logo

DOUBLE MEDICAL TECHNOLOGY INC. — Investor Relations & Filings

Ticker · 002901 ISIN · CNE1000032W7 LEI · 836800DECKX5CGFNMD42 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 963 across all filing types
Latest filing 2022-04-25 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002901

About DOUBLE MEDICAL TECHNOLOGY INC.

https://www.double-medical.com

Double Medical Technology Inc. specializes in the development, manufacturing, and distribution of medical devices, with a primary focus on orthopedic solutions. The company's extensive product portfolio includes trauma fixation systems, spinal implants, joint prosthesis, and neurosurgical devices. Additionally, it provides specialized surgical instruments and advanced wound care products. Double Medical emphasizes research and innovation to deliver clinically effective solutions for complex musculoskeletal conditions. Its manufacturing processes adhere to international quality standards, ensuring the reliability of its implants and instruments used in hospitals and surgical centers worldwide. The company serves a global market, providing comprehensive support for orthopedic surgeons through its diverse range of reconstructive and regenerative medical technologies.

Recent filings

Filing Released Lang Actions
关于签署募集资金四方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a four-party supervision agreement related to the management and use of funds raised through a non-public stock issuance. It details the amount raised, the parties involved, the account details, and the terms of the supervision agreement. There are no financial statements, comprehensive financial data, or detailed financial performance analysis present. The document is relatively short (2794 characters) and serves as a formal announcement of a capital raising and fund management agreement rather than a full report or financial statement. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2022-04-25 Chinese
北京德恒（厦门）律师事务所关于大博医疗科技股份有限公司2018年限制性股票激励计划首次授予部分第三个解除限售期及预留授予部分第二个解除限售期解除限售的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2018 restricted stock incentive plan of a company. It discusses the approval, authorization, and conditions for the lifting of stock sale restrictions under the incentive plan, including detailed legal compliance and audit confirmations. The document is not a financial report, earnings release, or management discussion, but a legal opinion related to stock incentive plan implementation and compliance. It is not a proxy solicitation or voting result announcement, nor a board or management change notice. The document is a standalone legal opinion on a specific corporate action related to stock incentives, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Capital/Financing Update or Director's Dealing. The document length is substantial and contains detailed legal analysis, not just an announcement or certification, but it is not a financial or audit report itself.
2022-04-22 Chinese
北京德恒（厦门）律师事务所关于大博医疗科技股份有限公司2021年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2021 Annual General Meeting (AGM) of a company. It details the legality of the AGM's convening, attendance, agenda, and voting results. It includes specific voting outcomes on various proposals presented at the AGM. The document is not the AGM materials or presentation itself, but a legal opinion on the AGM proceedings and results. This type of document is best classified under Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports official voting results and validates the AGM process. The document length is sufficient and contains detailed voting data, not just an announcement of a report or a brief notice, so it is not RPA or RNS.
2022-04-22 Chinese
独立董事关于公司第二届董事会第二十四次会议审议事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters related to the company's restricted stock incentive plan, including the lifting of restrictions on certain shares and the granting of reserved restricted stock. It references compliance with relevant laws and regulations and provides an independent opinion on these corporate governance matters. The document does not contain financial statements or quarterly/yearly financial results, nor is it a transcript or announcement of voting results. It is a governance-related document focusing on board-level decisions and opinions regarding stock incentive plans. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to board decisions and senior management matters.
2022-04-22 Chinese
北京德恒（厦门）律师事务所关于大博医疗科技股份有限公司2021年限制性股票激励计划预留授予的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the company's 2021 restricted stock incentive plan reserved grant. It discusses the approval, authorization, eligibility, quantity, grant date, grant price, and conditions of the stock incentive plan. The document is a legal opinion and not a financial report, earnings release, or management discussion. It is not an announcement of voting results or a proxy solicitation. It is a standalone legal opinion related to a stock incentive plan, which fits best under the category of Regulatory Filings (RNS) as it does not fit other specific categories like Capital/Financing Update or Remuneration Information. The document is over 8000 characters and contains detailed legal analysis, not just a brief announcement or certification. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-04-22 Chinese
监事会关于2018年限制性股票激励计划可解除限售激励对象名单的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal opinion from the Supervisory Board regarding the verification of the list of incentive recipients eligible for lifting restrictions on restricted stock under the company's 2018 restricted stock incentive plan. It discusses compliance with relevant laws and regulations, eligibility criteria, and confirms that 283 incentive recipients meet the conditions for lifting stock restrictions. The document is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement related to stock incentive plan compliance and approval. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a regulatory announcement related to corporate governance and stock incentive compliance, best classified under Regulatory Filings (RNS). The document length is short (1129 characters), and it is a formal supervisory opinion rather than a report or presentation.
2022-04-22 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.